WO2025209499 - POLθ INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF AND USE
National phase entry is expected:
Publication Number
WO/2025/209499
Publication Date
09.10.2025
International Application No.
PCT/CN2025/086748
International Filing Date
02.04.2025
Title **
[English]
POLθ INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF AND USE
[French]
INHIBITEUR DE POLθ ET COMPOSITION PHARMACEUTIQUE DE CELUI-CI ET UTILISATION
[Chinese]
Polθ抑制剂及其药物组合物和应用
Applicants **
ALICORN PHARMACEUTICAL CO., LTD
Inventors
LU, Pingbo
YANG, Jiale
ZHU, Hui
WANG, Minchao
DENG, Minjie
WANG, Zhi
Priority Data
202410398889.7
03.04.2024
CN
202410601956.0
14.05.2024
CN
202411073608.7
06.08.2024
CN
202411238132.8
04.09.2024
CN
202510088603.X
20.01.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2316 | |
| EPO | Filing, Examination, Granting | 14248 | |
| Japan | Filing, Examination, Granting | 2247 | |
| South Korea | Filing, Examination, Granting | 2467 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
26,018
Contact Us
Abstract[English]
The present invention relates to a heterocyclic compound for inhibiting the activity of a DNA polymerase Theta(Polθ), a stereoisomer, a tautomer, or a pharmaceutically acceptable salt of the compound and a use thereof in preparation of a drug for treating or preventing cancer. Specifically, provided are a compound as shown in formula I or a stereoisomer form and pharmaceutically acceptable salt thereof, wherein the definition of each group is as described in the description. The compound has relatively high Polθ inhibitory activity, so that the compound can be used for treating diseases related to overexpression of Polθ.[French]
La présente invention concerne un composé hétérocyclique pour inhiber l'activité d'une ADN polymérase Theta(Polθ), un stéréoisomère, un tautomère, ou un sel pharmaceutiquement acceptable du composé et une utilisation de celui-ci dans la préparation d'un médicament pour le traitement ou la prévention du cancer. Plus particulièrement, l'invention concerne un composé tel que représenté dans la formule I ou une forme stéréoisomère et un sel pharmaceutiquement acceptable de celui-ci, la définition de chaque groupe étant telle que décrite dans la description. Le composé a une activité inhibitrice de Polθ relativement élevée, de telle sorte que le composé peut être utilisé pour traiter des maladies liées à la surexpression de Polθ.[Chinese]
涉及抑制DNA聚合酶Theta(Polθ)活性的杂环化合物、立体异构体、互变异构体或其药学上可接受的盐及其在制备用于治疗或预防癌症的药物中的用途，具体地，提供了一种式I所示的化合物或其立体异构体形式、药学上可接受的盐，其中，各基团的定义如说明书中所述。所述的化合物具有较高的Polθ抑制活性，因此可以用于治疗与Polθ过表达相关的疾病。